▼ Summary
– Vinay Prasad is leaving the FDA for the second time in April, following a tenure marked by controversy and self-destructive decisions.
– His controversial actions included rejecting an mRNA vaccine against scientific advice, imposing new hurdles for a Huntington’s gene therapy, and publicly attacking a company.
– His departure is seen positively by financial analysts and the biotech industry, with affected companies like UniQure seeing stock increases.
– This is his second exit under the Trump administration, having previously resigned and been quickly reinstated over another gene therapy controversy.
– Prasad held top regulatory roles despite lacking direct regulatory experience, gaining prominence through online criticism of pandemic policies and podcast appearances.
Vinay Prasad, a former FDA vaccine regulator whose time at the agency was defined by contentious decisions, is preparing to leave his post for a second time. Commissioner Marty Makary noted in a social media announcement that Prasad will depart in April, stating he achieved a great deal during his year-long tenure. This exit follows a series of disruptive actions that have unsettled agency staff, industry leaders, and patient advocates alike.
Prasad’s departure comes after several controversial moves that critics argue damaged the agency’s credibility and process. These include an unexpected rejection of an mRNA vaccine, a decision made against the advice of agency scientists and later swiftly reversed, and imposing new clinical trial demands for a Huntington’s disease gene therapy, a move viewed as unfairly shifting approval requirements. He further sparked outrage by publicly criticizing the therapy’s developer, UniQure, and faces allegations of fostering a hostile workplace through the mistreatment of FDA employees.
The cumulative effect of these actions created significant turmoil within the FDA and across the broader biopharmaceutical landscape. Financial analysts and the biotechnology sector have largely welcomed the news of his exit, with some calling it a major positive development for companies, particularly those focused on rare diseases. Several firms that previously encountered regulatory setbacks under Prasad saw their stock prices rise following the announcement, with UniQure’s shares jumping approximately 25 percent.
This marks Prasad’s second departure from the agency under the current administration. He initially resigned last July amid controversy over his handling of a Duchenne muscular dystrophy gene therapy and criticism from political activists, only to be reinstated to his position within two weeks.
Upon his return, Prasad assumed significant authority as the FDA’s chief medical and scientific officer and director of the Center for Biologics Evaluation and Research (CBER). This placed him as the primary regulator for vaccines, gene therapies, and similar biologic products. His qualifications for these pivotal roles were frequently questioned, as he arrived with no prior regulatory experience or specialized expertise in vaccines or gene therapy. His prominence and appointment were largely fueled by his vocal online criticism of pandemic public health measures, including COVID-19 vaccines, and his frequent appearances on various media platforms.
(Source: Ars Technica)
